Consistent stratification in two distinct risk categories:
*In clinical studies, BCI Intermediate had a statistically similar risk of late (5-10 year) recurrence as the BCI High risk group; thus risk categories for risk of late recurrence are reported as Low or High only
Clinically, BCI could allow many women with early-stage oestrogen-receptor-positive breast cancer to avoid unnecessary extended antihormonal treatment, and could be an important method to aid the management of residual risk after 5 years of adjuvant hormonal treatment.
– Sgroi et al, TransATAC study, Lancet Oncol, 20131
The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.
This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.